{
    "name": "ioversol",
    "comment": "Rx",
    "other_names": [
        "Optiray"
    ],
    "classes": [
        "Iodinated Contrast Media"
    ],
    "source": "https://reference.medscape.com/drug/optiray-ioversol-343759",
    "pregnancy": {
        "common": [
            "Postmarketing data with product use in pregnant women are insufficient to determine if there is risk of drug-associated adverse developmental outcomes; literature reports show that product crosses placenta and is visualized in digestive tract of exposed infants after birth; product crosses placenta and reaches fetal tissues in small amounts; in animal reproduction studies, no adverse developmental effects were observed following intravenous administration of ioversol to pregnant rats and rabbits at doses 0.35 and 0.71 times, respectively, the maximum recommended human dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information about presence of product in human or animal milk, effects of drug on breastfed infant, or effects of drug on milk production; however, iodinated contrast agents are excreted unchanged in human milk in very low amounts with poor absorption from gastrointestinal tract of breastfed infant; the developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for product and any potential adverse effects on breastfed infant from product or from underlying maternal condition; interruption of breastfeeding after exposure to iodinated contrast agents is not necessary because potential exposure of breastfed infant to iodine is small; however, a lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 8 hours (approximately 5 elimination half-lives) after product administration in order to minimize drug exposure to breast fed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Administer procedure at facilities where staff is familiar with the recognition and treatment of allergic reactions",
                "When administering large doses use caution in patients with renal impairment or concurrent renal/hepatic impairment",
                "Neurologic events including paralysis following cerebral arteriography, arteriography of blood vessels , and spinal arteriography, reported",
                "Myocardial infarctions and stroke reported with angiographic procedures",
                "Thyroid storm reported with the use of iodinated contrast media",
                "Use caution in patients with multiple myeloma and pheochromocytoma",
                "Serious adverse events reported with inadvertent administration of iodinated contrast media intrathecally",
                "Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Not for intrathecal use (may cause death, convulsions, cerebral hemorrhage, coma, paralysis, ARF)",
                "Symptomatic hyperthyroidism"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Inhibits blood coagulation",
                "Caution in severe renal impairment, combined renal/hepatic disease, severe thyrotoxicosis, myelomatosis, anuria, pheochromocytoma, sickle cell, CHF, chronic alcoholism, severe arterial/venous disease",
                "May cause renal failure in patients with advanced vascular disease, diabetes; should be well hydrated before/after procedure; do not use laxatives, diuretics, or preparatory dehydration prior to administering product",
                "Obtain a history of allergy, hypersensitivity, or prior hypersensitivity reactions to iodinated contrast agents; always have emergency resuscitation equipment and trained personnel available and monitor all patients for hypersensitivity reactions",
                "Allergies (bronchial asthma, hay fever, food allergies) reported",
                "Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions should be considered; reports indicate that such pretreatment does not prevent serious life-threatening reactions, but may reduce both their incidence and severity",
                "General anesthesia may be indicated in the performance of some procedures in selected patients; however, a higher incidence of adverse reactions has been reported in these patients",
                "In angiographic procedures, the possibility of dislodging plaques or damaging or perforating the vessel wall should be considered during catheter manipulations and contrast medium injection; test injections to ensure proper catheter placement are suggested",
                "Angiography should be avoided whenever possible in patients with homocystinuria because of risk of inducing thrombosis and embolism",
                "Patients with congestive heart failure should be observed for several hours following procedure to detect delayed hemodynamic disturbances which may be associated with transitory increase in circulating osmotic load",
                "Extreme caution during injection of contrast medium is necessary to avoid extravasation; this is especially important in patients with severe arterial or venous disease",
                "Selective coronary arteriography should be performed only in selected patients and those in whom expected benefits outweigh procedural risk; inherent risks of angiocardiography in patients with chronic pulmonary emphysema must be weighed against necessity for performing this procedure",
                "Fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiographic procedures; to minimize thromboembolic events use meticulous angiographic technique; avoid blood remaining in contact with syringes containing the product, which increases risk of clotting; avoid angiocardiography in patients with homocystinuria because of risk of inducing thrombosis and embolism",
                "Contraindicated in patients with symptomatic hyperthyroidism; thyroid storm reported following intravascular use of iodinated radiopaque agents in patients with hyperthyroidism or with autonomously functioning thyroid nodule; evaluate risk in patients before using product",
                "Hypertensive crisis has occurred after use of iodinated radiopaque contrast agents in patient with pheochromocytoma; closely monitor patients when administering product if pheochromocytoma or catecholamine-secreting paraganglioma is suspected; inject minimum amount of product necessary and have measures for treatment of hypertensive crisis readily available",
                "Iodinated contrast agents may promote sickling in individuals who are homozygous for sickle cell disease; hydrate patients prior to and following product administration; use product only if necessary imaging information cannot be obtained with alternative imaging modalities, and inject minimum amount necessary",
                "Severe cutaneous adverse reactions(SCAR), including Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS), may develop from 1 hr to several weeks after intravascular contrast agent administration; reaction severity may increase and time to onset may decrease with repeat administration of contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions; avoid administering product to patients with history of severe cutaneous adverse reaction to product"
            ],
            "specific": [
                {
                    "type": "Thyroid dysfunction in pediatric patients",
                    "description": [
                        "Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression reported after both single exposure and multiple exposures to iodinated contrast media in pediatric patients 0 to 3 years of age",
                        "Younger age, very low birth weight, prematurity, underlying medical conditions affecting thyroid function, admission to neonatal or pediatric intensive care units, and congenital cardiac conditions are associated with increased risk of hypothyroidism after ICM exposure",
                        "Pediatric patients with congenital cardiac conditions may be at greatest risk given that they often require high doses of contrast during invasive cardiac procedures",
                        "An underactive thyroid during early life may be harmful for cognitive and neurological development and may require thyroid hormone replacement therapy",
                        "After exposure to iodinated contrast media, individualize thyroid function monitoring in pediatric patients 0-3 years of age based on underlying risk factors, especially in term and preterm neonates",
                        "Pediatric patients 0-3 years of age warrant closer monitoring because an underactive thyroid during early life may be harmful to motor, hearing, and cognitive development and may require transient T4 replacement therapy"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate and ioversol both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cidofovir",
            "description": {
                "common": "cidofovir and ioversol both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "ioversol and neomycin PO both increase  nephrotoxicity and/or ototoxicity. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin and ioversol both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metformin",
            "description": {
                "common": "ioversol increases levels of metformin by decreasing renal clearance. Contraindicated. Acute renal failure or lactic acidosis may result.  D/c metformin 48 hr before and after imaging study."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "streptozocin",
            "description": {
                "common": "ioversol and streptozocin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "ioversol and tacrolimus both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teicoplanin",
            "description": {
                "common": "ioversol and teicoplanin both increase  nephrotoxicity and/or ototoxicity. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acyclovir",
            "description": {
                "common": "acyclovir and ioversol both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adefovir",
            "description": {
                "common": "adefovir and ioversol both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "aldesleukin increases toxicity of ioversol by unknown mechanism. Use Caution/Monitor. Risk of atypical adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "capreomycin",
            "description": {
                "common": "capreomycin and ioversol both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carboplatin",
            "description": {
                "common": "carboplatin and ioversol both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cephaloridine",
            "description": {
                "common": "cephaloridine and ioversol both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cisplatin and ioversol both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colistin",
            "description": {
                "common": "colistin and ioversol both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "ioversol and elvitegravir/cobicistat/emtricitabine/tenofovir DF both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "foscarnet",
            "description": {
                "common": "ioversol and foscarnet both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "ioversol and gentamicin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iodixanol",
            "description": {
                "common": "iodixanol decreases effects of ioversol by unknown mechanism. Use Caution/Monitor. Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with thyroid carcinoma. Decreased efficacy lasts for 6-8 weeks. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "ioversol increases toxicity of metformin by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Administration of intravascular iodinated contrast agents in metformin-treated patients has led to rare cases of acute decrease in renal function and the occurrence of lactic acidosis. The American College of Radiology Guidelines (2018) recommend temporarily stopping metformin in patients with eGFR is <30 mL/min/1.73 m2 or who are undergoing arterial catheter studies that might result in emboli to the renal arteries. Continue to withhold metformin for 48 hr subsequent to the procedure and reinstituted only after renal function has been reevaluated and found to be normal. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methotrexate",
            "description": {
                "common": "ioversol and methotrexate both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methoxyflurane",
            "description": {
                "common": "ioversol and methoxyflurane both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "ioversol and oxaliplatin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paromomycin",
            "description": {
                "common": "ioversol and paromomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "ioversol and pentamidine both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peramivir",
            "description": {
                "common": "ioversol increases levels of peramivir by decreasing renal clearance. Use Caution/Monitor. Caution when peramivir coadministered with nephrotoxic drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "ioversol and polymyxin B both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab",
            "description": {
                "common": "ioversol and rituximab both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "ioversol and rituximab-hyaluronidase both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptomycin",
            "description": {
                "common": "ioversol and streptomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin",
            "description": {
                "common": "ioversol and tobramycin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vancomycin",
            "description": {
                "common": "ioversol and vancomycin both increase  nephrotoxicity and/or ototoxicity. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, ioversol.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Myocardial infarction",
            "percent": null
        },
        {
            "name": "arrhythmia",
            "percent": null
        },
        {
            "name": "atrioventricular block complete",
            "percent": null
        },
        {
            "name": "atrioventricular block",
            "percent": null
        },
        {
            "name": "nodal rhythm",
            "percent": null
        },
        {
            "name": "bradycardia",
            "percent": null
        },
        {
            "name": "angina pectoris",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "Ear and labyrinth disorders",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "tinnitus",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Vision blurred",
            "percent": null
        },
        {
            "name": "periorbital edema",
            "percent": null
        },
        {
            "name": "conjunctivitis",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "abdominal pain",
            "percent": null
        },
        {
            "name": "dysphagia",
            "percent": null
        },
        {
            "name": "dry mouth",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "hematoma",
            "percent": null
        },
        {
            "name": "extravasation",
            "percent": null
        },
        {
            "name": "pyrexia",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "chills",
            "percent": null
        },
        {
            "name": "injection site pain",
            "percent": null
        },
        {
            "name": "injection site hematoma",
            "percent": null
        },
        {
            "name": "extravasation",
            "percent": null
        },
        {
            "name": "pyrexia",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "fatigue chills",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "Injury",
            "percent": null
        },
        {
            "name": "poisoning",
            "percent": null
        },
        {
            "name": "and procedural complications",
            "percent": null
        },
        {
            "name": "Heart injury",
            "percent": null
        },
        {
            "name": "vascular pseudoaneurism",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Acidosis",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Muscular weakness",
            "percent": null
        },
        {
            "name": "muscle spasms",
            "percent": null
        },
        {
            "name": "back pain",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Cerebral infarction",
            "percent": null
        },
        {
            "name": "aphasia",
            "percent": null
        },
        {
            "name": "tremor",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "presyncope",
            "percent": null
        },
        {
            "name": "headache",
            "percent": null
        },
        {
            "name": "paraesthesia",
            "percent": null
        },
        {
            "name": "dysgeusia",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Hallucination",
            "percent": null
        },
        {
            "name": "visual hallucination",
            "percent": null
        },
        {
            "name": "disorientation",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Urinary retention",
            "percent": null
        },
        {
            "name": "renal pain",
            "percent": null
        },
        {
            "name": "polyuria",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Laryngeal edema",
            "percent": null
        },
        {
            "name": "hypoxia",
            "percent": null
        },
        {
            "name": "pulmonary edema",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "hyperventilation",
            "percent": null
        },
        {
            "name": "cough",
            "percent": null
        },
        {
            "name": "sneezing",
            "percent": null
        },
        {
            "name": "nasal congestion",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "swelling face",
            "percent": null
        },
        {
            "name": "hyperhidrosis",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "arterial spasm",
            "percent": null
        },
        {
            "name": "vasospasm",
            "percent": null
        },
        {
            "name": "vasodilation",
            "percent": null
        },
        {
            "name": "flushing",
            "percent": null
        },
        {
            "name": "Endocrine disorders",
            "percent": null
        },
        {
            "name": "Hyperthyroidism",
            "percent": null
        },
        {
            "name": "hypothyroidism",
            "percent": null
        },
        {
            "name": "Eye disorders and administrative site conditions",
            "percent": null
        },
        {
            "name": "Injection site reactions",
            "percent": null
        },
        {
            "name": "nerve injury",
            "percent": null
        },
        {
            "name": "extravasation",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "induration",
            "percent": null
        },
        {
            "name": "bruising",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylactoid shock",
            "percent": null
        },
        {
            "name": "with multi",
            "percent": null
        },
        {
            "name": "organ failure and cardiorespiratory arrest",
            "percent": null
        },
        {
            "name": "anaphylactic shock",
            "percent": null
        },
        {
            "name": "anaphylactic",
            "percent": null
        },
        {
            "name": "hypersensitivity reaction",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Acute kidney injury",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "acute generalized exanthematous pustulosis",
            "percent": null
        }
    ]
}